Innovation Pharmaceuticals Inc (OP:IPIX)

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases

June 21, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing

Performance

52-Week Range 99.6% below 52-week high

0.0002

0.0052W Low 0.0552W High

1 Week 88.9% below 1-week high

0.001W Low 0.001W High

Innovation Pharmaceuticals Inc (IPIX) traded between $0.00 and $0.05 over the past 52 weeks and last traded at $0.00, 99.6% below its 52-week high. Over the past week it ranged between $0.00 and $0.00.

Past 12 Months

-75.0%

N/A

-33.3%

-80.0%

-66.7%

1W -$0.00

3M -$0.00

6M -$0.00

YTD -$0.00

1Y -$0.00

IPIX was -66.7% over the past year, -33.3% over six months, -80.0% year to date, -75.0% in the last week.

12 Months vs Market

IPIX

-66.7%

DIA

+8.2%

SPY

+10.8%

QQQ

+10.8%

IWM

+14.3%

Over the past 12 months IPIX returned -66.7% versus DIA (Dow) +8.2%, SPY (S&P 500) +10.8%, QQQ (Nasdaq 100) +10.8% and IWM (Russell 2000) +14.3%.

Volume & Liquidity

167.1K

278.1K

232.3K

223.1K

YTD

188.6K

229.9K

IPIX's 3-month average daily volume is 232.3K.

More News

June 05, 2023

Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications

April 17, 2023

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers

March 15, 2023

Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission

February 23, 2023

Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement

January 09, 2023

Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis

December 13, 2022

Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family

November 28, 2022

Scientific Poster on Innovation Pharmaceuticals Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference

November 15, 2022

NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"

October 26, 2022

New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals' Brilacidin Presented at 2022 Military Health System Research Symposium

September 15, 2022

Innovation Pharmaceuticals' Investment in BT BeaMedical Helping Advance New Surgical Laser Platform

September 13, 2022

Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox

August 05, 2022

Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate

July 22, 2022

Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate

July 22, 2022

Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium

June 28, 2022

Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers

June 23, 2022

Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology

June 15, 2022

Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin

March 15, 2022

Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases

March 07, 2022

Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022

These OTC Securities Had the Most Trading Activity in November ↗

December 16, 2021

Via Benzinga

December 07, 2021

Innovation Pharmaceuticals Provides Brilacidin Program Update

November 18, 2021

Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin's Potential Inclusion in Government-Sponsored COVID-19 Trials

November 12, 2021